Navigation Links
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
Date:11/24/2008

vement disorders without some of the complications of standard dopaminergic treatments.

Parkinson's disease is an age-related, progressive, degenerative brain disease that currently affects one out of 100 people over the age of 60 (approximately 500,000 people in the U.S. alone). It is believed to be caused by a loss of nerve cells in the midbrain. The resulting symptoms include tremor, abnormal gait and posture, loss of balance, muscle stiffness and slowness of movements. These symptoms often severely compromise a patient's ability to lead a normal life. All currently available treatment options enhance directly or indirectly the effect of the neurotransmitter dopamine in the brain. While these treatments are often effective in the initial phase of the disease, their ability to control the symptoms of Parkinson's disease declines over time. Moreover, after several years of therapy these medications frequently induce additional troublesome and disabling motor fluctuations that can last several hours per day. At this stage, patients often experience periods of loss of movement control during the day (so-called "off"-time), which alternates with periods of relatively good motor functions (so-called "on"-time).

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUG
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
2. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
3. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
4. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
5. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
6. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Schering-Plough Reports Top-Line Results of the IDEAL Study
11. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... MILAN , June 19, 2013 ... in fluctuating Parkinson,s disease (PD) patients as add-on ... clinically important improvement in motor symptoms in fluctuating ...   Newron Pharmaceuticals S.p.A. ("Newron"), a ... and pain therapies, and its partner Zambon S.p.A., ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6
... 2011 Asante Solutions, Inc. (Asante), a medical device ... the CE mark for its Pearl Insulin Pump, the ... The CE mark is a European proof of conformity ... environmental requirements. Asante has begun discussions with potential distribution ...
... 12, 2011 PRA International, a leading Clinical Research Organization, ... (SRM) group will speak at the World Drug Safety Congress ... will also host an exhibit at booth #2. ... chair the first breakout stream, "Operational Safety," on 13 April ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:6/19/2013)... mantra of neurologists treating stroke victims has been "time equals ... quickly to receive a drug that dissolves the stroke-causing blood ... tissue is saved or lost. , But specific ... giving the intravenous drug known as a tissue plasminogen ... (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... 2013 Chicago is cracking down on bed ... 50th Chicago Wards will require landlords to exterminate any and ... The ordinance also makes tenants responsible for reporting ... requests – which often include disposing of furniture, bedding, and ... reported that it did more bed bug business in Chicago ...
(Date:6/19/2013)... TN (PRWEB) June 19, 2013 ... PT continuing education course with an ... physical therapy assistants and occupational therapists. ... education course supplemented by an online continuing ... intermediate level algorithmic problem solving skills needed to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 A blow to ... headache follows immediately or within minutes to hours. It’s ... Concussion is classified as a mild traumatic brain injury. ... concussion are headache, amnesia and confusion. But many other ... the initial injury. These may include ongoing headaches, dizziness, ...
(Date:6/19/2013)... 19, 2013 The website HealthNewsWires.com has ... resistance, its harmful effects and tips to manage and ... video from HealthNewsWires.com, the author defines insulin resistance ... efficiently remove and process glucose from the bloodstream. ... by all cells, organs and systems of the body ...
Breaking Medicine News(10 mins):Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2
... YORK, March 19 Prescribing Reference, Inc. (PRI),and Medicos, ... have now downloaded eMPR, the desktop and mobile version ... in the United States,have relied on the print editions ... Now eMPR is providing the exact same drug,information on ...
... German . , Transport processes in the cells ... roads. Molecular motors, which are special protein molecules, act as ... it along microtubules, which are the roads of the cell. ... trucks and can only move as far as the beginning ...
... using stem cell transplants are advancing promising treatments for ... cord injury, and heart disease. Now, scientists think that ... from diabetes or cancer. However, important questions need answers: ... stem cells be used to provide insulin cells that ...
... market-leading provider,of software for the control, management and ... its interactions with the,media through the use of ... world,s leading pharmaceutical companies, is a,truly international company, ... its,corporate office in London and major Research & ...
... 19 Mirion Technologies, the,leading global provider of ... industry, will showcase two new products at the,10th ... from,March 25th - 28th., Mirion,s Health Physics ... Contamination Monitor. The TwoStep Exit monitor is a,new ...
... COLORADO SPRINGS, Colo., March 19 Thanks to ... Foundation (NSPF), Washington,State University researchers plan to create ... will be the world,s premiere center for aquatic ... a physician and research,professor in WSU,s College of ...
Cached Medicine News:Health News:eMPR Digital Drug Reference Reaches 50,000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 2Health News:eMPR Digital Drug Reference Reaches 50,000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 3Health News:Tug of war in the cells 2Health News:Tug of war in the cells 3Health News:Coming soon: Cell therapies for diabetes, cancer? 2Health News:Coming soon: Cell therapies for diabetes, cancer? 3Health News:Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations 2Health News:Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations 3Health News:Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition 2Health News:Exploring the 'Aaah' ... $1 Million Grant Advances Aquatic Health Research 2
... Libert Coronary Stent System ... of lesion access and ... a low crossing profile, ... catheter, the performance of ...
... Long series in colonies, rows, and microplatesthat ... the multichannel pipette is becoming an ever-increasing ... use) was the main reason that the ... 8- or 12-channel pipette provides effective, precise, ...
... Digital Multichannel, with it's streamlined ... of routine laboratory tasks. The ... features: Soft-touch tip ejection, Super ... (0.5-10ul models), Entire pipette autoclavable, ...
... and value!, Comfortable feel and less ... , Finer control while pipetting with smooth, ... ejection with long, lever tip ejector , ... without the need for recalibration , Easy-to-read ...
Medicine Products: